Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature
- PMID: 1373705
- DOI: 10.1002/ijc.2910510220
Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature
Abstract
Seven mesothelioma cell lines, established from patients with pleural mesothelioma, exhibited substantial heterogeneity regarding in vitro morphology and growth characteristics. Media conditioned by these cell lines and by MeT5A normal mesothelial cells were examined for (i) colony formation on human bone-marrow cells, (ii) hematopoietic growth-factor content and (iii) mitogenic activity on mesothelioma cells. Colony-stimulating activity was produced only by the ZL34 cell line. Analysis of conditioned media by ELISA revealed that all mesothelioma cell lines constitutively produced IL-6, while the MeT5A normal mesothelial cells did not; in addition, GM-CSF and G-CSF were detected in the supernatant of the ZL34 cell line. Using a 3H-thymidine incorporation assay, we showed that all mesothelioma cell lines produced mitogenic activity in the culture supernatant, in contrast to the MeT5A normal mesothelial cells. The mitogenic effect of the hematopoietic growth factors detected in mesothelioma culture supernatants was tested on mesothelioma cells and on MeT5A normal mesothelial cells: IL-6, GM-CSF and G-CSF did not stimulate any DNA synthesis. Our results suggest that these hematopoietic growth factors do not act as autocrine growth factors. A common feature of this panel of mesothelioma cell lines is the production of IL-6; although the biological significance of the aberrant production of cytokines by mesotheliomas remains unclear, IL-6 might be involved in paraneoplastic syndromes such as thrombocytosis.
Similar articles
-
Transcription of genes encoding granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 6 receptors and lack of proliferative response to exogenous cytokines in nonhematopoietic human malignant cell lines.Cancer Res. 1993 Jul 1;53(13):3139-44. Cancer Res. 1993. PMID: 8319222
-
Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro.Blood. 1989 Aug 15;74(3):940-6. Blood. 1989. PMID: 2787682
-
Bladder carcinoma cell line KU-19-19-derived cytokines support proliferation of growth factor-dependent hematopoietic cell lines: modulation by phorbol ester, interferon-gamma and interleukin-1 beta.Biochem Biophys Res Commun. 1998 Jan 26;242(3):497-501. doi: 10.1006/bbrc.1997.8002. Biochem Biophys Res Commun. 1998. PMID: 9464244
-
Autocrine growth promotion by multiple hematopoietic growth factors in the established renal cell carcinoma line KU-19-20.Cell Tissue Res. 2000 Sep;301(3):353-67. doi: 10.1007/s004410000235. Cell Tissue Res. 2000. PMID: 10994781
-
Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.Leukemia. 1996 Apr;10(4):588-99. Leukemia. 1996. PMID: 8618433 Review.
Cited by
-
miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.Oncotarget. 2015 Sep 15;6(27):23480-95. doi: 10.18632/oncotarget.4346. Oncotarget. 2015. PMID: 26125439 Free PMC article.
-
Use of preclinical models for malignant pleural mesothelioma.Thorax. 2021 Nov;76(11):1154-1162. doi: 10.1136/thoraxjnl-2020-216602. Epub 2021 Mar 10. Thorax. 2021. PMID: 33692175 Free PMC article. Review.
-
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.Mol Cancer. 2007 Oct 22;6:66. doi: 10.1186/1476-4598-6-66. Mol Cancer. 2007. PMID: 17953743 Free PMC article.
-
Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis.J Transl Med. 2024 Apr 30;22(1):402. doi: 10.1186/s12967-024-05205-8. J Transl Med. 2024. PMID: 38689325 Free PMC article. Review.
-
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.PLoS One. 2013 Jun 20;8(6):e65903. doi: 10.1371/journal.pone.0065903. Print 2013. PLoS One. 2013. PMID: 23840376 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials